Effect of low-dose aspirin on platelet aggregation inhibition in patients with rheumatoid arthritis
Effect of low-dose aspirin on platelet aggregation inhibition in patients with rheumatoid arthritis
نویسندگان: مهرزاد حاج علیلوی بناب , امیر قربانی حق جو , فروغ قاسمی , علیرضا خبازی اسکویی , آیدا مالک مهدوی
کلمات کلیدی: Aspirin, Thromboxane B2, Platelet Aggregation, Coronary Artery Disease, Rheumatoid Arthritis
نشریه: 0 , 4 , 7 , 2019
| نویسنده ثبت کننده مقاله |
آیدا مالک مهدوی |
| مرحله جاری مقاله |
تایید نهایی |
| دانشکده/مرکز مربوطه |
بیماری های بافت همبند |
| کد مقاله |
70515 |
| عنوان فارسی مقاله |
Effect of low-dose aspirin on platelet aggregation inhibition in patients with rheumatoid arthritis |
| عنوان لاتین مقاله |
Effect of low-dose aspirin on platelet aggregation inhibition in patients with rheumatoid arthritis |
| ناشر |
5 |
| آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ |
بلی |
| عنوان نشریه (خارج از لیست فوق) |
Journal of Research in Clinical Medicine |
| نوع مقاله |
Original Article |
| نحوه ایندکس شدن مقاله |
ایندکس شده سطح چهار – سایر سایت های تخصصی |
| آدرس لینک مقاله/ همایش در شبکه اینترنت |
|
| Introduction:The risk for coronary artery disease (CAD) and mortality has increased in patients with rheumatoid arthritis (RA). Aspirin has anti-thrombotic effects and causes reduction in CAD occurrence in high-risk individuals. The objective of present project was evaluating the influence of low-dose aspirin on inhibition of platelet aggregation in patients with RA. Forty-eight subjects with RA diagnosed based on the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 criteria and age- and sex-matched healthy participants were studied. All subjects received 81 mg/day aspirin for 10 days. Level of the serum thromboxane B2 (sTxB2), a permanent metabolite of thromboxane A2 (TxA2), was measured before and after therapy using enzyme-linked immunosorbent assay (ELISA) kit. The impotency to decrease sTxB2 production to less than 10 ng/ml indicates suboptimal suppression of platelet aggregation via aspirin. Low-dose aspirin decreased sTxB2 significantly compared with baseline in patients with RA [median interquartile range (IQR): 25.72 (11.78, 90.10) to 7.74 (5.80, 8.82), P < 0.001] and in healthy controls [median (IQR): 40.50 (33.25, 50.90) to 7.30 (4.75, 8.85), P < 0.001]. No remarkable changes were seen in sTxB2 between patients and controls after adjustment (P > 0.050). Pharmacologic influence of aspirin was suboptimal in 6.25% of cases in the presence of higher erythrocyte sedimentation rate (ESR) and in 2.7% of controls. Low-dose aspirin decreased sTxB2 significantly only in patients with Framingham Risk Score (FRS) < 10%. Low-dose aspirin decreased sTxB2 level and suppressed platelet aggregation and therefore, was effective in primary prevention of cardiovascular (CV) events in patients with RA; however, additional studies are required to reach accurate conclusions. |
| نام فایل |
تاریخ درج فایل |
اندازه فایل |
دانلود |
| jarcm-7-110.pdf | 1398/09/30 | 1003938 | دانلود |